Neogenix Oncology members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers
ROCKVILLE, MD, USA | April 1, 2011 | Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers. The presentation is scheduled at the American Association of Cancer Research (AACR) 102nd Annual Meeting being held April 1-6, 2011 at the Orange County Convention Center, Orlando, FL, USA.
NEO-101 (NPC-1C, or Ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and colorectal cancer and is currently in Phase I clinical trials at The Johns Hopkins University Hospital, Duke University Medical Center and North Shore University/Long Island Jewish Medical Center. NEO-101 is the first in the Neogenix pipeline of antibodies intended to target specific cancers. The NEO-101 target appears to be a variant of MUC5AC that is expressed specifically by human colon and pancreatic tumor tissues and cell lines that in testing to date, have only occasionally shown, minimal and weak cross-reactivity to certain normal GI tract tissues. The preclinical data to be presented includes in vitro mechanism of action, immunofluorescent cell staining, in vivo anti-tumor efficacy, bio-distribution, and toxicokinetic studies.
“Neogenix is committed to building our preclinical knowledge base, of both NEO-101 and its target molecule, which is critical to understanding the pathology biology behind these cancers,” said Neogenix Chief Executive Officer, Philip M. Arlen, MD.
Poster Presentation Information:
Abstract Title: Pre-clinical studies of a novel antibody to treat pancreatic and colorectal cancers
Poster Session Date/Time: Immunology 6; Tuesday April 5th at 1:00pm-5:00pm.
Permanent Abstract ID: 4584
Location: Exhibit Hall A4-C; Poster Session 31; Poster #26
The full abstract can be accessed through the AACR website http://www.aacr.org/ or the Neogenix Oncology website, www.neogenix.com. The complete study presentation poster will also be available on the Neogenix website, following the presentation.
About Neogenix Oncology
Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, breast, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work at its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic test for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NEO-101 antibody in patients with metastatic pancreatic and colorectal cancer. NEO-201 and NEO-301 are in preclinical development towards IND submission.
SOURCE: Neogenix Oncology
Post Views: 34
Neogenix Oncology members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers
ROCKVILLE, MD, USA | April 1, 2011 | Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers. The presentation is scheduled at the American Association of Cancer Research (AACR) 102nd Annual Meeting being held April 1-6, 2011 at the Orange County Convention Center, Orlando, FL, USA.
NEO-101 (NPC-1C, or Ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and colorectal cancer and is currently in Phase I clinical trials at The Johns Hopkins University Hospital, Duke University Medical Center and North Shore University/Long Island Jewish Medical Center. NEO-101 is the first in the Neogenix pipeline of antibodies intended to target specific cancers. The NEO-101 target appears to be a variant of MUC5AC that is expressed specifically by human colon and pancreatic tumor tissues and cell lines that in testing to date, have only occasionally shown, minimal and weak cross-reactivity to certain normal GI tract tissues. The preclinical data to be presented includes in vitro mechanism of action, immunofluorescent cell staining, in vivo anti-tumor efficacy, bio-distribution, and toxicokinetic studies.
“Neogenix is committed to building our preclinical knowledge base, of both NEO-101 and its target molecule, which is critical to understanding the pathology biology behind these cancers,” said Neogenix Chief Executive Officer, Philip M. Arlen, MD.
Poster Presentation Information:
Abstract Title: Pre-clinical studies of a novel antibody to treat pancreatic and colorectal cancers
Poster Session Date/Time: Immunology 6; Tuesday April 5th at 1:00pm-5:00pm.
Permanent Abstract ID: 4584
Location: Exhibit Hall A4-C; Poster Session 31; Poster #26
The full abstract can be accessed through the AACR website http://www.aacr.org/ or the Neogenix Oncology website, www.neogenix.com. The complete study presentation poster will also be available on the Neogenix website, following the presentation.
About Neogenix Oncology
Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, breast, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work at its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic test for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NEO-101 antibody in patients with metastatic pancreatic and colorectal cancer. NEO-201 and NEO-301 are in preclinical development towards IND submission.
SOURCE: Neogenix Oncology
Post Views: 34
